FDA Finalizes ICH M7(R2) Guidance on Mutagenic Impurity Assessment and Acceptable Intake Calculations

Impurity control programs across drug development and commercial manufacturing now have a revised regulatory baseline: FDA has finalized the ICH M7(R2) guidance on assessment and control of DNA reactive (mutagenic) impurities, alongside two supplemental documents covering compound-specific acceptable intake (AI) calculations and a dedicated Q&A resource. The finalization closes a review cycle opened under docket FDA-2022-D-0055 and sets enforceable expectations for how manufacturers characterize and limit mutagenic impurities to reduce potential carcinogenic risk.

The package comprises three documents: the core M7(R2) guidance, an addendum applying ICH M7 principles to compound-specific AI calculations, and a Q&A document addressing implementation scenarios. Prepared under the auspices of the International Council for Harmonisation (ICH) and issued jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, the guidance is designed to harmonize mutagenic impurity assessment globally, carrying direct implications for submissions targeting multiple regulatory jurisdictions.

For QA directors and regulatory affairs leads, the addendum on compound-specific AI calculations is the most operationally consequential document. Where previous programs relied on the default Threshold of Toxicological Concern (TTC) limits, the addendum formalizes the methodology for deriving compound-specific limits when sufficient carcinogenicity data exist, a distinction that affects specification-setting, risk assessments, and the supporting documentation expected in CTD Module 3. Manufacturing teams should audit existing impurity control strategies against the updated framework, particularly where synthetic routes generate known or potential mutagenic intermediates.

The Q&A supplement addresses practical classification and control questions that have generated inconsistent industry interpretation since the original M7 guidance. Regulatory leads preparing or updating drug master files, ANDAs, or NDAs should cross-reference the Q&A document against current impurity sections before the next submission cycle, as reviewers at CDER and CBER will apply the finalized framework during technical assessment.

Comments on the guidance remain open under standard 21 CFR 10.115(g)(5) provisions and can be submitted via the FDA docket portal or in writing to Dockets Management, FDA, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852, referencing docket number FDA-2022-D-0055.

The measurable near-term checkpoint is alignment of existing impurity risk assessments and specifications with the compound-specific AI methodology detailed in the M7(R2) Addendum before the next scheduled regulatory submission or product lifecycle review.

Source: FDA Center for Drug Evaluation and Research / Center for Biologics Evaluation and Research via FDA Guidance Documents RSS Feed, 27 May 2026. Docket: FDA-2022-D-0055.